Edesa Biotech, Inc.
No enriched coverage for $EDSA in the last 7 days.
No SEC Form 4 filings for $EDSA in the last 30 days.
Boundless Bio (BOLD) agreed to an all-stock merger with private Serapha Bio; it expects a pre-close cash dividend and plans to trade as Serapha on Nasdaq under “AATD” in Q4 2026. Monopar (MNPR) said its ALXN1840 Wilson disease NDA is on track for mid-2026. Galectin (GALT) reached FDA agreement on key Phase 3 MASH protocol elements; final protocol due Q3 2026.
Edesa Biotech, Inc. (EDSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 exh_101.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is dated as of June 10, 2026, by and among Edesa Biotech, Inc., a British Columbia corporation (the “ Company ”), and each of the entities listed
Edesa Biotech (Nasdaq: EDSA) reported its fiscal Q2 2026 results and provided clinical updates. The company is advancing preparations for a Phase 2 study of EB06 in vitiligo, with site activation and recruitment targeted for mid-2026. Additionally, Edesa reported positive Phase 3 data for paridiprubart in Acute Respiratory Distress Syndrome (ARDS), showing consistent treatment benefits across various severity and comorbidity subgroups.
Recent EDSA coverage spans financial news, market movers and corporate actions.
Recruitment start timing is a near-to-medium term operational catalyst that can improve sentiment and trading liquidity.
The 8-K discloses a new equity financing structure (common shares + pre-funded warrants) that can be dilutive and may pressure near-term pricing, while registration rights can improve liquidity for investors.
Edesa Biotech's recent positive Phase 3 data for ARDS and progress in vitiligo trials suggest potential upside for the company's stock.
Edesa Biotech's upcoming Phase 2 trial for EB06 targeting vitiligo suggests potential upside for the company's stock, especially if the trial results are favorable.
Edesa Biotech announced its upcoming conference schedule, indicating active engagement in investor relations and potential upcoming developments.
alphai scores every news story that mentions EDSA with an AI model for sentiment and relevance, and aggregates insider trades from Edesa Biotech, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Boundless Bio (BOLD) agreed to an all-stock merger with private Serapha Bio; it expects a pre-close cash dividend and plans to trade as Serapha on Nasdaq under “AATD” in Q4 2026. Monopar (MNPR) said its ALXN1840 Wilson disease NDA is on track for mid-2026. Galectin (GALT) reached FDA agreement on key Phase 3 MASH protocol elements; final protocol due Q3 2026.
7 min readEdesa Biotech, Inc. (EDSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 exh_101.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is dated as of June 10, 2026, by and among Edesa Biotech, Inc., a British Columbia corporation (the “ Company ”), and each of the entities listed
4 min readEdesa Biotech (Nasdaq: EDSA) reported its fiscal Q2 2026 results and provided clinical updates. The company is advancing preparations for a Phase 2 study of EB06 in vitiligo, with site activation and recruitment targeted for mid-2026. Additionally, Edesa reported positive Phase 3 data for paridiprubart in Acute Respiratory Distress Syndrome (ARDS), showing consistent treatment benefits across various severity and comorbidity subgroups.
4 min readEdesa Biotech plans to begin enrollment for its Phase 2 clinical study of EB06, a potential treatment for nonsegmental vitiligo, in mid-2026. The company has secured partnerships and initiated site outreach, with patient recruitment expected to start in Canada upon regulatory approval. EB06 targets the CXCL10 chemokine to prevent or reverse depigmentation and has shown biological activity and a favorable safety profile in previous evaluations.
3 min readTORONTO, Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Edesa Biotech, Inc. ( Nasdaq:EDSA ) , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business development staff plan to ...
2 min readTORONTO, Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Edesa Biotech, Inc. ( NASDAQ:EDSA ) , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business development staff plan to ...
2 min readTORONTO, Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- Edesa Biotech, Inc. ( Nasdaq:EDSA ) , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics ( HDTs ) for immuno-inflammatory diseases, today announced positive results from a Phase 3 study evaluating the company's ...
3 min readStudy met primary and secondary endpoints Paridiprubart demonstrated a relative reduction in the risk of death of 25% Treatment provided patients with clinically meaningful improvement in survival and recovery Paridiprubart exhibited consistent safety and tolerability profile
3 min readEdesa Biotech ( NASDAQ:EDSA ) , a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases, released its fiscal third quarter results on August 8, 2025, covering the period ended June 30, 2025.
3 min readTORONTO, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Edesa Biotech, Inc. ( Nasdaq:EDSA ) , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and ...
3 min read
